Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):48-51. Review.

PMID:
23444510
2.

Choice of first-line treatment for metastatic prostate cancer.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):51. No abstract available.

PMID:
23444511
3.

Locally advanced prostate cancer: effective treatments, but many adverse effects.

[No authors listed]

Prescrire Int. 2013 Jan;22(134):18-20, 22-3. Review.

PMID:
23367679
4.

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.

Cochrane Database Syst Rev. 2014 Jun 30;(6):CD009266. doi: 10.1002/14651858.CD009266.pub2. Review.

PMID:
24979481
5.

Hormone therapy of prostatic bone metastases.

Huben RP.

Adv Exp Med Biol. 1992;324:305-16.

PMID:
1492625
6.

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.

Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.

Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Review.

7.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
8.

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.

Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ.

Ann Intern Med. 2000 Apr 4;132(7):566-77. Erratum in: Ann Intern Med. 2005 Nov 15;143(10):764-5.

PMID:
10744594
9.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
10.

[Androgen deprivation for advanced prostate cancer].

Heidenreich A, Pfister D, Ohlmann CH, Engelmann UH.

Urologe A. 2008 Mar;47(3):270-83. doi: 10.1007/s00120-008-1636-2. Review. German.

PMID:
18273599
11.

Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.

Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T; Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.

J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17.

PMID:
18635218
12.

Second-line treatment of metastatic prostate cancer. Prednisone and radiotherapy for symptom relief.

[No authors listed]

Prescrire Int. 2013 Mar;22(136):74-8. Review.

PMID:
23593699
13.

Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.

Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE.

Eur Urol. 1997;32(4):391-5; discussion 395-6.

PMID:
9412794
14.

[Keyrole of endocrinology in the victory against prostate cancer].

Labrie F.

Bull Cancer. 2006 Sep;93(9):949-58. Review. French.

PMID:
16980238
15.

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.

Bayoumi AM, Brown AD, Garber AM.

J Natl Cancer Inst. 2000 Nov 1;92(21):1731-9.

16.

[First line therapy in the treatment of metastatic prostate cancer].

Sakai H, Kanetake H.

Gan To Kagaku Ryoho. 2003 Jan;30(1):43-9. Review. Japanese.

PMID:
12557704
17.

Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.

Mahler C, Verhelst J, Denis L.

Clin Pharmacokinet. 1998 May;34(5):405-17. Review.

PMID:
9592622
18.

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.

Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N.

Cancer. 2002 Jul 15;95(2):361-76. Review.

19.

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.

Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.

Eur Urol. 1996;29 Suppl 2:105-9.

PMID:
8717471
20.

Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.

Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Kovacev O, Robertson R, Francis L, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G.

Radiother Oncol. 2003 Sep;68(3):255-67.

PMID:
13129633
Items per page

Supplemental Content

Write to the Help Desk